The incretin space has moved fast. Semaglutide captured headlines. Tirzepatide’s dual GLP-1/GIP agonism pushed efficacy further. Now researchers are turning their attention to the next step — and retatrutide is the compound at the centre of that conversation.

Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — representing a significant advancement in the pharmacology of metabolic disease research. PubMed Central

Australian Peptides supplies high-purity Retatrutide 20mg for research purposes, making it accessible to the Australian scientific community as Phase 3 data continues to emerge.

Three Receptors, One Molecule

Most researchers familiar with peptide research in Australia will know GLP-1 agonists well. What makes retatrutide distinct is the addition of glucagon receptor agonism to the GLP-1/GIP dual mechanism.

Each receptor contributes something different. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite. GIP receptor activation complements GLP-1’s insulin-sensitising effects and plays a role in fat metabolism. Glucagon receptor activation drives energy expenditure — increasing lipolysis and thermogenesis through mechanisms that GLP-1 and GIP agonism alone cannot replicate.

The result is a research peptide that addresses energy intake, glucose regulation, and energy expenditure through three distinct but synergistic pathways — making it one of the most mechanistically interesting compounds available for metabolic research in Australia right now.

Phase 2 Data: Weight Loss at a Different Scale

The phase 2 results are among the most discussed in the peptide and metabolic research space over the past two years.

In phase 2 trials, retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity, and 16.9% in those with type 2 diabetes after 36 weeks. In the T2D cohort, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c at or below 6.5%. PubMed Central

That 24.2% figure exceeds what has been observed in trials of approved dual agonists at comparable timepoints — a meaningful signal for researchers studying the incremental value of glucagon receptor co-activation.

Phase 3: The TRIUMPH Programme

Retatrutide is now deep into a large Phase 3 programme with results emerging across multiple indications.

Eli Lilly is studying retatrutide across Phase 3 trials covering obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Eli Lilly and Company

In December 2025, positive topline results from the TRIUMPH-4 Phase 3 trial were announced — both the 9mg and 12mg doses met all primary and key secondary endpoints, delivering significant weight loss alongside improvements in pain and physical function at 68 weeks. Seven additional Phase 3 trials are expected to complete in 2026. Eli Lilly and Company

Cardiometabolic and Liver Research

Beyond weight and glycaemic outcomes, retatrutide demonstrated improvements across multiple cardiometabolic parameters in phase 2 data. A separate Phase 2a trial published in Nature Medicine has also investigated retatrutide for metabolic dysfunction-associated steatotic liver disease — one of the most prevalent and under-treated metabolic conditions globally. PubMed Central

The glucagon receptor component is particularly relevant here, given glucagon’s established role in hepatic lipid metabolism and its capacity to reduce liver fat through mechanisms distinct from GLP-1 agonism alone.

Buy Retatrutide in Australia — For Research Use

Australian Peptides is one of Australia’s leading suppliers of research peptides, offering Retatrutide 20mg alongside a comprehensive catalogue including BPC-157, TB-500, GHK-Cu, MOTS-c, and peptide stacks including GLOW and KLOW. All products are independently tested for purity and supplied strictly for laboratory and scientific research purposes.

Retatrutide remains investigational globally as of May 2026 — not approved for human therapeutic use in Australia or any other jurisdiction. The full TRIUMPH Phase 3 dataset continues to emerge throughout 2026.

A Note on Research Use

All products supplied by Australian Peptides are intended for laboratory and scientific investigation only and are not approved for human therapeutic use in Australia. Nothing in this article constitutes medical advice or a recommendation for human use.